Solutions for Life Science & Diagnostics
anti-GFP HRP-DirecT Trial Size
Additional Information
anti-GFP HRP-DirecT Trial Size Specifications
| Background: | HRP-DirecT is a series of HRP conjugated primary antibodies developed by MBL. HRP-DirecT Series products don’t need secondary antibodies. That brings the following advantages: ①Total incubation time is cut in half. The reaction with the secondary antibody becomes unnecessary. In the shaking method, reaction time is only 30 minutes. Spend your evening doing more important things. Clear result No more heavy and light chain bands in Immunoprecipitation. The HRP conjugated primary antibody will not detect your precipitating antibody. Clear result helps your research. Usually, the secondary antibody amplifies the signal of an unconjugated primary antibody. Therefore, it is thought to be difficult to obtain a strong signal with a directly conjugated antibody. To overcome this hurdle, MBL has improved the HRP conjugation method. MBL’s HRP-DirecT Series yield strong signal with minimum background. Give it a try - the HRP-DirecT Series will not disappoint you. |
| Clonality: | Polyclonal |
| Conjugate: | HRP |
| Host Species: | Rabbit |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
| Isotype: | IgG |
| Product Type: | Primary Antibody |
| Shipping: | 4 |
| Size: | 10 μL |
| Status: | RUO |
| Storage: | 4 |
| Target: | GFP |
Applications:
There are no additional documents for anti-GFP HRP-DirecT Trial Size at this time.
There are no references for anti-GFP HRP-DirecT Trial Size at this time.
